CPT:炎症治疗的进展与局限

Clinical Pharmacology and Therapeutics

2017-10-01Editorial

7.266

影响因子

原标题:炎症:治疗进展和局限

① 随着对慢性炎症疾病的研究逐渐深入,一系列以炎症的主要触发因子(如TNFα、整合素、IL-6/IL-23等细胞因子)为靶点的新药,和粪菌移植等新型疗法,都取得了不错的效果;② 有研究表明,以IL-6为靶点的司妥昔单抗也能改善癌症预后,提示抗炎症治疗在癌症治疗中的潜在作用;③ 这些治疗手段的分子机制和可能存在副作用,如增加感染风险等;④ 未来应以寻找更精准的抗炎症的药物靶点为重心,以减少治疗副作用,而早期的检测和预防更为重要。

抗炎症治疗

图片

Title:
Inflammation: Treatment Progress and Limitations

DOI:
10.1002/cpt.792

Abstract & Authors展开

Abstract:
There is an increasing understanding on the etiology of chronic immune-mediated inflammatory diseases such as inflammatory bowel disease (IBD), psoriasis, or rheumatoid arthritis. Large consortia contributed to the elucidation of the genetics, for instance, of IBD identifying a number of genes involved in innate mucosal defense and immune tolerance (most prominent, e.g., NOD2) and other related processes. For a number of such diseases, common genetic susceptibility loci were identified, suggesting overlapping immune response pathways, although there is no causality of single genetic traits.(2) In particular, the elucidation of main triggers of inflammation like tumor necrosis factor alpha (TNFα), integrins, specific cytokines like interleukin (IL)-6 or IL-23 launched the successful development of new pharmacological approaches, leading to a tremendous improvement of therapeutic outcomes.

All Authors:
Ingolf Cascorbi

First Authors:
Ingolf Cascorbi

Correspondence:
Ingolf Cascorbi

查看PDF原文

已完成

请稍等...

提示
提示